A detailed history of Bank Of America Corp transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 1,212 shares of RPHM stock, worth $2,036. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,212
Previous 947 27.98%
Holding current value
$2,036
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.34 - $1.7 $355 - $450
265 Added 27.98%
1,212 $2,000
Q2 2024

Aug 14, 2024

SELL
$1.51 - $1.9 $5,173 - $6,509
-3,426 Reduced 78.34%
947 $1,000
Q1 2024

May 15, 2024

SELL
$1.59 - $1.74 $31,173 - $34,114
-19,606 Reduced 81.76%
4,373 $7,000
Q4 2023

Feb 14, 2024

BUY
$1.34 - $8.43 $24,110 - $151,680
17,993 Added 300.58%
23,979 $38,000
Q2 2023

Aug 14, 2023

BUY
$5.44 - $10.5 $27,858 - $53,770
5,121 Added 592.02%
5,986 $39,000
Q1 2023

May 12, 2023

BUY
$2.44 - $6.42 $702 - $1,848
288 Added 49.91%
865 $5,000
Q4 2022

Feb 10, 2023

SELL
$1.8 - $3.52 $30,567 - $59,776
-16,982 Reduced 96.71%
577 $1,000
Q3 2022

Nov 14, 2022

SELL
$2.35 - $4.85 $11,564 - $23,866
-4,921 Reduced 21.89%
17,559 $59,000
Q2 2022

Aug 12, 2022

SELL
$1.96 - $3.04 $36,060 - $55,929
-18,398 Reduced 45.01%
22,480 $59,000
Q1 2022

May 16, 2022

BUY
$2.94 - $9.07 $23,267 - $71,779
7,914 Added 24.01%
40,878 $121,000
Q4 2021

Feb 08, 2022

BUY
$6.07 - $9.68 $91,638 - $146,138
15,097 Added 84.5%
32,964 $282,000
Q3 2021

Nov 15, 2021

BUY
$6.28 - $11.07 $97,597 - $172,038
15,541 Added 668.14%
17,867 $133,000
Q2 2021

Sep 13, 2021

BUY
$7.78 - $15.0 $18,096 - $34,890
2,326 New
2,326 $22,000

Others Institutions Holding RPHM

About Reneo Pharmaceuticals, Inc.


  • Ticker RPHM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,479,600
  • Market Cap $41.1M
  • Description
  • Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...
More about RPHM
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.